Proteo, Inc./ Proteo Biotech AG: Proteo's Elafin Will Be Tested at the U.S. Army Medical Research Institute of Infectious Dis...
June 18 2010 - 4:25AM
Business Wire
Proteo, Inc. (OTCBB:PTEO; Frankfurter Freiverkehr: WKN: 925981)
and its wholly-owned subsidiary Proteo Biotech AG announced today
the signing of a cooperative research and development agreement
with the U.S. Army Medical Research Institute of Infectious
Diseases (USAMRIID). Under the agreement Proteo will provide
USAMRIID with Elafin and related scientific data in order to plan
and conduct preclinical research on the development of new
therapeutic strategies to combat life-threatening infectious
diseases.
Scientists from the U.S. Army Medical Research Institute of
Infectious Diseases are investigating therapies to treat
individuals that have become symptomatic after exposure to one of
the bacterial bio-threat agents (anthrax, plague, tularemia,
glanders or melioidosis). One direction their research has taken is
to attempt to mitigate or alter the immunological response that in
many cases is the ultimate cause of death in these infections. They
are interested in investigating if Proteo's Elafin could help as a
co-therapy with antibiotics.
Proteo's CEO, Birge Bargmann: »We are looking forward to the
results of the U.S. Army Medical Research Institute of Infectious
Diseases regarding the use of our Lead Product, Elafin, in
preclinical models«.
Further information on the clinical development program for
Elafin:
Proteo's drug substance Elafin is a natural human antagonist of
elastase and proteinase-3, two potent tissue destroying enzymes,
both of which participate in the inflammatory mechanism of a
variety of diseases. Elafin's ability to block these inflammation
promoting enzymes makes it a promising drug candidate for the
treatment of inflammatory lung diseases and severe reperfusion
injury. The excellent tolerability of intravenously administered
recombinant Elafin was demonstrated convincingly in a Phase I
clinical trial. The results of a Phase II clinical trial for the
treatment of postoperative inflammatory reactions of esophagus
carcinoma are currently being evaluated. Proteo's licensing and
development partner, Minapharm Pharmaceuticals SAE, has initiated a
further Phase II clinical trial on the use of Elafin in kidney
transplantation patients. This trial is concerned with the
prevention of acute organ rejection and chronic graft injury
(allograft nephropathy) and will be conducted at the University of
Cairo. As a further cooperation partner, the University of
Edinburgh is planning a clinical trial to test Elafin in the
context of bypass surgery after a heart attack.
About Proteo:
The company researches, develops and markets compounds for
biological and medical research as well as for use as
pharmaceuticals. The main focus is on anti-inflammatory drugs, in
particular on the human elastase inhibitor Elafin. Proteo intends
to out-license selected indications and to establish international
strategic alliances in order to open up new fields of application
and for marketing (www.proteo.us).
About USAMRIID:
USAMRIID, located at Fort Detrick, Maryland, is the lead medical
research laboratory for the U.S. Department of Defense's Biological
Defense Research Program, and plays a key role in national defense
and in infectious disease research. The Institute conducts basic
and applied research on biological threats resulting in medical
solutions (such as vaccines, drugs and diagnostics) to protect the
warfighter. While USAMRIID's primary mission is focused on the
military, its research often has applications that benefit society
as a whole. USAMRIID is a subordinate laboratory of the U.S. Army
Medical Research and Materiel Command. For more information, visit
www.usamriid.army.mil. The information contained in this press
release does not necessarily reflect the position or the policy of
the Government and no official endorsement should be inferred.
Forward-Looking Statements:
Certain statements in this news release may contain
forward-looking information within the meaning of Rule 175 under
the Securities Act of 1933 and Rule 3b-6 under the Securities
Exchange Act of 1934, and are subject to the safe harbor created by
those rules. All statements, other than statements of fact included
in this release, including, without limitation, statements
regarding potential future plans and objectives of the company, are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Technical
complications that may arise could prevent the prompt
implementation of any strategically significant plan(s) outlined
above. The company cautions that these forward looking statements
and risks and uncertainties involved are further qualified by other
factors including, but not limited to those set forth in the
company's Form 10-K filing and other filings with the United States
Securities and Exchange Commission. The company undertakes no
obligation to publicly update or revise any statements in this
release, whether as a result of new information, future events or
otherwise.
Proteo (GM) (USOTC:PTEO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Proteo (GM) (USOTC:PTEO)
Historical Stock Chart
From Jul 2023 to Jul 2024